Claim OwnershipEAU Podcasts
Subscribed: 37Played: 957
Subscribe
© 2024 EAU Podcasts
Description
This is the official podcast channel of the European Association of Urology and the European School of Urology. The EAU Podcast is your source for the latest information across the full urological spectrum. Take your clinical practice to new heights and tune in!
97 Episodes
Reverse
In this special edition of EAU Podcasts, experts Prof. Paolo Gontero and Prof. Alexandra Masson-Lecomte met in person at the EAU Annual Congress (EAU24) to discuss the newest updates to the EAU Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma (UTUC).Panel Chairs Prof. Paolo Gontero and Prof. Alexandra Masson-Lecomte cover points of change in the UTUC guidelines, including genetic testing recommendations, risk classifications, and treatment recommendations.
In 'Episode 3' of the series “What young urologists need to know", titled "Mentorship and peer support: Navigating urology together”, Prof. Prokar Dasgupta (GB) and Assoc. Prof. Juan Luis Vásquez (DK) talk about the crucial role of mentorship and peer support in the field of urology.They discuss how guidance from experienced mentors and collaboration among peers can enhance professional growth, clinical skills, and overall well-being in the challenging realm of urological practice. Whether it's navigating complex cases or advancing career trajectories, this episode offers invaluable insights for aspiring and established urologists alike, emphasising the power of mentorship and camaraderie in shaping successful medical careers.
Tune in to 'Episode 2' of the series “What young urologists need to know", titled "Academic - clinics balance: How to achieve it?", where Prof. Bhaskar Somani (GB) and Ass. Prof. Giorgio Gandaglia (IT) navigate the delicate equilibrium between academia and clinical practice in urology. In their discussion they share insightful strategies and personal experiences on balancing research commitments with patient care responsibilities. Whether you're a seasoned practitioner or an aspiring academic, this podcast offers invaluable guidance on maintaining balance between advancing medical knowledge and delivering optimal healthcare outcomes.Tune in to this enriching discussion that promises to inspire and inform!
In 'Episode 1' of the series on "What young urologists need to know", segment 2 covers the topic of "Balancing the life of a young urologist". Dr. Thomas Tailly (BE) and Dr. Michiel Sedelaar (NL) offer a comprehensive exploration of the age-old question: Is it truly possible to strike a balance between work and well-being? Dr. Tailly and Dr. Sedelaar delve into the intricate interplay between work and well-being. Through their insightful discussion and evidence-based insights, you can gain ideas on how to achieve a harmonious balance between professional commitments and personal fulfilment. Tune in to learn some practical strategies to cope in today's fast-paced world of urology.
In 'Episode 3', the final of the series on "Metastatic renal cell carcinoma", Dr. Andrea Mari (IT) talks with Dr. Chiara Ciccarese (IT) from the Medical Oncology Unit at Fondazione Policlinico Universitario A. Gemelli IRCCS, in Rome. Together they have an in-depth discussion on "Beyond first-line treatment strategies for metastatic renal cell carcinoma".Dr. Mari and Dr. Ciccarese delve into recent advancements in managing mRCC, including therapeutic options, and their impact on patient care and outcomes. From targeted therapies to immunotherapies, they offer a comprehensive exploration of the evolving treatment landscape.Tune in to this engaging and informative conversation with two distinguished experts at the forefront of cancer research and treatment.
In 'Episode 2' of the series on "Metastatic renal cell carcinoma", Dr. Andrea Mari (IT) talks to Dr. Laura Marandino (GB) about "The first-line treatment strategies for metastatic renal cell carcinoma".Dr. Andrea Mari and Dr. Laura Marandino unravel the complexities of mRCC management, exploring the latest advancements, therapeutic options, and their implications for patient care. From targeted therapies to immunotherapies, they provide a comprehensive overview of the evolving treatment landscape.Tune in as we navigate through this insightful conversation with two distinguished guests at the forefront of cancer research and treatment.This podcast episode was recorded before ASCO GU 2024. Please note that information discussed may not reflect updates from the conference. We encourage listeners to verify the latest information independently.
UROONCO PCa associate editor Dr. Constance Thibault (FR) talks to Prof. Christophe Hennequin from Saint-Louis Hospital, France about the GETUG-AFU 18 trial results he presented at ASCO GU24 in San Francisco. Prof. Hennequin shares details on the design of the study, followed by the trial results of long-term dose escalation (80 vs 70Gy) combined with long-term androgen deprivation in high-risk prostate cancer. For more details on this study, you can read this abstract on the UROONCO Prostate Cancer educational platform.
In 'Episode 1' of a series on "Metastatic renal cell carcinoma", Assist. Prof. Andrea Mari (IT) and Prof. Ketan Badani (US) discuss "The role of cytoreductive nephrectomy for metastatic renal cell carcinoma ".Assist. Prof. Andrea Mari and Prof. Ketan Badani delve into the pivotal role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma (mRCC). They talk about the rationale behind this surgical intervention, its impact on patient outcomes, and the evolving landscape of treatment strategies in advanced kidney cancer.Whether you're a healthcare professional or someone seeking insights into cutting-edge cancer therapies, this discussion promises to illuminate the complexities of renal cell carcinoma management.
In this podcast, UROONCO RCC chief editor Dr. Carmen Mir (ES) interviews Prof. Michael Hofman from the Peter MacCallum Cancer Centre, Australia, on the results of his study “First-in-human safety, imaging and dosimetry of [68Ga]Ga-DPI-4452, a novel CA IX-targeting peptide, in patients with clear cell renal cell carcinoma (ccRCC)”. Prof. Hofman discusses the data he presented at ASCO GU24 in San Francisco and suggests that these first-in-human findings with radiolabelled DPI-4452 are encouraging for the subsequent evaluation of treatment with [177Lu]Lu-DPI-4452.[68Ga]Ga-DPI-4452 provides exceptional images in patients with ccRCC without clinically significant toxicity. Very high SUVs and tumour-to-background ratios suggest potential for use in both diagnostics and patient selection for therapy. The tumour retention and rapid elimination support potential of [177Lu]Lu-DPI-4452 radioligand therapy. For more details on this study, you can read the abstract on the UROONCO Kidney Cancer educational platform.
In this podcast, UROONCO RCC chief editor Dr. Carmen Mir interviews Prof. Nizar Tannir from the University of Texas, MD Anderson Cancer Center, USA, on the long-term follow-up data from the phase 3 CheckMate 214 trial: Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC). Prof. Tannir summarises the history and stability of the Checkmate 214 trial results over the last 8 years, before discussing the latest data from his presentation at ASCO GU24 in San Francisco.For more details on this trail, you can read the abstract on the UROONCO Kidney Cancer educational platform.
In this podcast interview live from ASCO GU24 in San Francisco, UROONCO PCa associate editor Dr. Constance Thibault (FR) talks to medical oncologist Dr. Kim Chi from the University of British Columbia, Canada, about the CONTACT-2 trial. This randomised phase 3 trial aimed to evaluate the efficacy of cabozantinib + atezolizumab vs. second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).Dr. Chi shares his interpretation of the study design and the main outcomes, including the safety profile. During the interview, Dr. Chi also explains why he does not believe it will become the new standard of care for patients with mCRPC, and details the more preferrable options available for this patient population. For more details on this trial, you can read the abstract on the UROONCO Prostate Cancer educational platform.
In this podcast, UROONCO RCC chief editor Dr. Carmen Mir (ES) interviews Assoc. Prof. Pedro Barata from University Hospitals Seidman Cancer Center, USA, about the results of two adjuvant RCC studies: KEYNOTE-564; and CheckMate-914.Assoc. Prof. Barata explains the positive trial results of KEYNOTE-564, which is the first time there has been an overall survival advantage with a PD-1 inhibitor in the pure adjuvant setting in RCC. These results support adjuvant pembrolizumab as a standard of care after surgery.CheckMate-914 explored adjuvant nivolumab monotherapy versus placebo for patients with high-risk localised RCC post-nephrectomy. The trial had negative results as it did not meet its primary endpoint of disease-free survival improvement. In an expert analysis at ASCO GU24, Assoc. Prof. Barata presented on adjuvant treatment for RCC and the strategies on how to optimise patient selection for the new standard of care.For more details on these trials, you can also read the abstract on KEYNOTE-564 and the abstract on CheckMate-914 on the UROONCO Kidney Cancer educational platform.
In this podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) interviews medical oncologist Dr. Andrea Apolo from the National Cancer Institute, USA, on the results of the AMBASSADOR study, which she presented at ASCO GU24. Dr. Apolo shares details on the rationale of the AMBASSADOR study: An open-label, randomised, phase III trial, evaluating the efficacy and safety of pembrolizumab as an adjuvant treatment in muscle-invasive and locally advanced urothelial carcinoma (MIUC). Dr. Apolo discusses the positive second interim data for disease-free survival (DFS), with a medium DFS with adjuvant pembrolizumab of 29 months vs. 14 months in the observation arm. Based on these findings, Dr. Apolo stated that pembrolizumab is active and should be considered as a therapy for patients in the adjuvant setting. For more details on this study, you can read this abstract on the UROONCO Bladder Cancer educational platform.
In this podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) interviews Dr. Srikala Sridhar (CA), about her abstract she recently presented at ESMO 2023, PET-MUSE: “Impact of positron emission tomography (PET) imaging on staging of muscle-invasive bladder cancer (MIBC)”.Dr. Sridhar shares details on the rationale and design of the study, as well as some interesting results.For more details on this study, you can read this abstract on the UROONCO Bladder Cancer educational platform.
In this edition, Dr. Aisling Nic an Riogh (IE), a member of the EAU Guidelines panel for Non-neurogenic female LUTS, discusses bladder outlet obstruction (BOO) in women.Dr. Nic an Riogh defines bladder outlet obstruction, its prevalence, and the various symptoms. She further explains that BOO can be divided into two main groups, anatomical (physical or mechanical), and functional (non-anatomical, non-urogenic). It is diagnosed via urodynamics, and Dr. Nic an Riogh discusses the various tests available. Lastly, the guidelines for conservative treatment and surgical options are discussed in detail.
In this podcast, UROONCO RCC board members, chief editor Dr. Carmen Mir (ES), and associate editors Dr. Riccardo Bertolo (IT) and Dr. Teele Kuusk (GB), discuss the progress made in the field of kidney cancer during 2023, and what is anticipated for 2024.Some topics discussed include the game-changing ZIRCON trial, OpeRa trial, and 3D models in PN and single-port RPN, as well as SBRT – FASTRACK II. Adjuvant IO, first-line mRCC treatments (KEYNOTE-426), and RN is also reviewed.The main WHO classification changes are highlighted, as well as the classification changes that are expected in 2024. This podcast concludes with a summary of the RCC trials to look forward to in the coming year.
In 'Episode 4' of the series "What do young urologists need to know," 'Segment 1' covers the topic of "Navigating the transition from residency to professional urology practice." Assoc. Prof. Emre Şener (TR) discusses networking and building professional relationships in urology with Dr. Amelia Pietropaolo (GB).Assoc. Prof. Şener and Dr. Pietropaolo delve into the critical aspects of establishing robust connections within the urology field. They emphasise the significance of networking for young professionals, highlighting strategies to initiate and nurture meaningful relationships with mentors, colleagues, and industry peers. The episode provides actionable tips on leveraging social media, attending conferences, and engaging in collaborative projects to expand one's professional network.Ultimately, the episode aims to empower young urologists with the skills needed to forge impactful connections, fostering career growth and knowledge-exchange within the urology community.
This is 'Episode 3' of the podcast series "What do young urologists need to know," 'Segment 1': "Navigating the transition from residency to professional urology practice." Dr. Elena Seguí-Moya (GB) converses with Prof. Sabine Brookman-May (US) about preparing for a job interview.The discussion highlights essential steps and strategies for excelling in a job interview within the specialised field of urology, emphasising the importance of showcasing clinical skills or research experience. Additionally, the episode offers valuable tips on effectively communicating one's passion for the field and aligning personal goals with the prospective employer's vision, ensuring a successful and promising start to a urology career.
In 'Episode 2' of the series on "What young urologists need to know," segment 1 covers the topic of "Navigating the transition from residency to professional urology practice." Dr. Bhavan Prasad Rai (GB) and Dr. Guido Kamphuis (NL) delve into the aspects of preparing and maintaining an effective CV. Dr. Rai and Dr. Kamphuis talk about how your CV should highlight relevant experiences and achievements, exploring the key elements that make a standout CV in the competitive field of urology. They emphasise the importance of tailoring your CV to reflect your career aspirations, including research, clinical, and academic pursuits specific to urology.Additionally, Dr. Rai and Dr. Kamphuis touch upon the significance of regularly updating your CV to reflect ongoing professional development, certifications, and new skills in this rapidly evolving field. Tune in for expert insights and practical tips that will help young urologists present themselves effectively on paper and pave the way for a successful career trajectory.
In 'Episode 1' of the series on "What young urologists need to know," segment 1 covers the topic of "Navigating the transition from residency to professional urology practice." Assoc. Prof. Veeru Kasivisvanathan (GB) and Ms. María Pilar Moreno-Fontela (ES) discuss the significant transition from residency to independent practice in this episode titled: "My residency is finished: how will my life change?" Assoc. Prof. Kasivisvanathan and Ms. Moreno-Fontela delve into the challenges and adjustments that come with newfound autonomy, such as managing patient loads, navigating administrative tasks and adapting to a different work-life balance.The episode sheds light on the shifts experienced by these urologists, offering insights and advice on coping mechanisms, time management, and building a supportive network in the field. Additionally, it explores strategies for continual learning and growth as they embark on this new phase of their medical careers.
Comments
Download from Google Play
Download from App Store
United States